IRWD Quote, Financials, Valuation and Earnings

Amgen has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 6.9%. Ironwood Pharmaceuticals's return on equity of -- beat Amgen's return on equity of 66.87%.

Ironwood Pharmaceuticals has a consensus price target of $3.34, signalling upside risk potential of 359.61%. On the other hand Amgen has an analysts' consensus of $317.12 which suggests that it could grow by 14.37%. Given that Ironwood Pharmaceuticals has higher upside potential than Amgen, analysts believe Ironwood Pharmaceuticals is more attractive than Amgen.

Ironwood Pharmaceuticals has a beta of 0.297, which suggesting that the stock is 70.281% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.29% to investors and pays a quarterly dividend of $2.38 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Amgen quarterly revenues of $9.1B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Amgen's net income of $627M. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Amgen's PE ratio is 36.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.33x versus 4.48x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

Bristol-Myers Squibb has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 0.58%. Ironwood Pharmaceuticals's return on equity of -- beat Bristol-Myers Squibb's return on equity of -46.27%.

Ironwood Pharmaceuticals has a consensus price target of $3.34, signalling upside risk potential of 359.61%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $59.48 which suggests that it could grow by 20.83%. Given that Ironwood Pharmaceuticals has higher upside potential than Bristol-Myers Squibb, analysts believe Ironwood Pharmaceuticals is more attractive than Bristol-Myers Squibb.

Ironwood Pharmaceuticals has a beta of 0.297, which suggesting that the stock is 70.281% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.408, suggesting its less volatile than the S&P 500 by 59.151%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 4.96% to investors and pays a quarterly dividend of $0.62 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Bristol-Myers Squibb quarterly revenues of $12.3B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Bristol-Myers Squibb's net income of $72M. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Bristol-Myers Squibb's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.33x versus 2.07x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 23.96%. Ironwood Pharmaceuticals's return on equity of -- beat Merck &'s return on equity of 40.25%.

Ironwood Pharmaceuticals has a consensus price target of $3.34, signalling upside risk potential of 359.61%. On the other hand Merck & has an analysts' consensus of $110.66 which suggests that it could grow by 41.87%. Given that Ironwood Pharmaceuticals has higher upside potential than Merck &, analysts believe Ironwood Pharmaceuticals is more attractive than Merck &.

Ironwood Pharmaceuticals has a beta of 0.297, which suggesting that the stock is 70.281% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.05% to investors and pays a quarterly dividend of $0.81 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Merck & quarterly revenues of $15.6B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Merck &'s net income of $3.7B. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Merck &'s PE ratio is 11.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.33x versus 3.09x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 3.52% compared to Ironwood Pharmaceuticals's net margin of 2.31%. Ironwood Pharmaceuticals's return on equity of -- beat Pfizer's return on equity of 8.91%.

Ironwood Pharmaceuticals has a consensus price target of $3.34, signalling upside risk potential of 359.61%. On the other hand Pfizer has an analysts' consensus of $30.16 which suggests that it could grow by 36.24%. Given that Ironwood Pharmaceuticals has higher upside potential than Pfizer, analysts believe Ironwood Pharmaceuticals is more attractive than Pfizer.

Ironwood Pharmaceuticals has a beta of 0.297, which suggesting that the stock is 70.281% less volatile than S&P 500. In comparison Pfizer has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.954%.

Ironwood Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.63% to investors and pays a quarterly dividend of $0.43 per share. Ironwood Pharmaceuticals pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Ironwood Pharmaceuticals quarterly revenues are $90.5M, which are smaller than Pfizer quarterly revenues of $17.8B. Ironwood Pharmaceuticals's net income of $3.2M is lower than Pfizer's net income of $410M. Notably, Ironwood Pharmaceuticals's price-to-earnings ratio is 126.50x while Pfizer's PE ratio is 15.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ironwood Pharmaceuticals is 0.33x versus 1.98x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.